About this trial
Cesarean birth is a common surgical procedure. After cesarean birth, postsurgical pain may delay recovery, interfere with maternal-newborn bonding, and reduce the breastfeeding if not adequately controlled. Postpartum analgesia has become a common concern.
Many adjuvant drugs used for peripheral nerve blocks as( N-methyl-d-aspartate (NMDA) receptor antagonists , Magnesium , Ephedrine , Dexamesathone , Fentanyl , Midazolam and Neostigmine) The potential of neostigmine as an adjuvant in peripheral nerve block is through its action to increase acetylcholine at muscarinic junctions of peripheral nerves. 500 mcg neostigmine was used as adjuvant to local anesthetic in an axillary brachial plexus block leads to decreased pain and less use of analgesics in the first 24 hours postoperatively with no incidence of adverse effects.
Eligibility criteria
Qualifiers
Age from 19 to 40 years old
American Society of Anesthesiologists (ASA) physical status II patients
Singleton pregnancies with a gestational age of at least 37 weeks.
Patients undergoing spinal anesthesia for cesarean delivery via a Pfannenstiel incision with exteriorization of the uterus.
Disqualifiers
Age < 19 or > 40 years.
Height<150 cm, weight < 60 kg, body mass index (BMI) ≥40 kg/m2.
Inability to comprehend or participate in the pain scoring system.
Contraindications to spinal anesthesia (Coagulopathy, increased intracranial pressure, or local skin infection).
Trial design
Treatments tested in this trial
- Bupivacaine-Neostigmine
- Bupivacaine
Treatment groups
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.